Now Available: Brazil Pharmaceuticals Competitive Intelligence Report Q4 2010

Nov. 25, 2010 - PRLog -- Brazil boasts some 550 pharmaceutical companies, which are largely generics-based. BMI estimates that the indigenous industry accounts for around 70% of the generics market segment, as measured in volume terms. However, the lower cost of domestically manufactured generics will continue to hamper the development of their value share of the total market. Nevertheless, in the table of the top 10 companies by sales revenue in 2009, domestic companies continued to occupy four places, indicating the strength of local manufacturing and the popularity of generic medicines in Brazil.

BMI believes that Brazil will continue to see investment from pharmaceutical companies owing to its strong potential and a relatively good risk profile. In terms of domestic manufacturing, the companies will continue to invest in local laboratories and production. According to Febrafarma, in 2007, all pharmaceutical companies operating in Brazil invested BRL1.5bn (US$701mn) in the country, much of which targeted improvements in production capacity and efficiency as well as to support new product launches. While domestic players invest considerably smaller sums than their foreign peers (which account for an estimated 80% of total investments in plant construction, modernisation and maintenance), they are making concerted efforts to modernise their facilities, also with a view to boosting exports.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/94268_brazil_pharmaceuticals_c...

Report Table of Contents:

Competitive Intelligence Analysis
- Pharmaceutical Industry - Competitive Landscape
- Table: Top 10 Pharmaceutical Companies In Brazil By Revenues 2008 and 2009
- Table: Top 10 Domestic Pharmaceutical Companies In Brazil By Revenues 2008 and 2009
- Foreign Drug Companies
- Domestic Drug Companies
- OTC Sector
Company Profiles
- Ache/Biosintetica
- EMS Sigma
- Eurofarma
- Medley
- Cristalia
- Sanofi-Aventis
- Pfizer
- Merck and Co
- Novartis
- GlaxoSmithKline (GSK)
- Roche
- Merck KGaA
- Nycomed/Altana
- Novo Nordisk
Market Attractiveness Analysis
- Market Summary
- Regulatory Regime
SWOT Analysis
- China Pharmaceuticals And Healthcare Industry SWOT
Risk/Reward Rating
- Pharmaceutical Business Environment Ratings
- Table: Americas Pharmaceutical Business Environment Ratings, Q410
- Rewards
- Risks
Business Development Directory

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.